糖尿病合并肝硬化的降糖治疗

Y. Sumida, M. Yoneda, K. Tokushige, M. Kawanaka, H. Fujii, M. Yoneda, Kento Imajo, H. Takahashi, YuichiroEguchi, M. Ono, Y. Nozaki, H. Hyogo, M. Koseki, Y. Yoshida, T. Kawaguchi, Y. Kamada, T. Okanoue, A. Nakajima
{"title":"糖尿病合并肝硬化的降糖治疗","authors":"Y. Sumida, M. Yoneda, K. Tokushige, M. Kawanaka, H. Fujii, M. Yoneda, Kento Imajo, H. Takahashi, YuichiroEguchi, M. Ono, Y. Nozaki, H. Hyogo, M. Koseki, Y. Yoshida, T. Kawaguchi, Y. Kamada, T. Okanoue, A. Nakajima","doi":"10.31031/IOD.2020.03.000566","DOIUrl":null,"url":null,"abstract":"Diabetes is associated with about 30% of liver cirrhosis and affects prognosis, carcinogenesis, and the onset of complications. In cirrhosis, fasting normal and postprandial hyperglycemia are often present, and evaluation by glucose tolerance test or continuous blood glucose measurement is also considered. Although no treatment strategy has been established, if renal function is maintained, metformin will be the first choice, but for renal dysfunction cases and metformin ineffective cases, insulin will be indicated. Although the efficacy and safety of incretin-related drugs and sodium-glucose cotransporter 2 inhibitors have not been established, they can be expected to be effective in cases with obesity. On the viewpoint of preventing sarcopenia and hepatocarcinogenesis, antidiabetic drugs should be selected. Exogenous insulin should be indicated for patients with Child C grade. This review discusses antidiabetic treatments for diabetes with liver cirrhosis.","PeriodicalId":170669,"journal":{"name":"Interventions in Obesity & Diabetes","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Antidiabetic Treatments for Diabetes with Liver Cirrhosis\",\"authors\":\"Y. Sumida, M. Yoneda, K. Tokushige, M. Kawanaka, H. Fujii, M. Yoneda, Kento Imajo, H. Takahashi, YuichiroEguchi, M. Ono, Y. Nozaki, H. Hyogo, M. Koseki, Y. Yoshida, T. Kawaguchi, Y. Kamada, T. Okanoue, A. Nakajima\",\"doi\":\"10.31031/IOD.2020.03.000566\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diabetes is associated with about 30% of liver cirrhosis and affects prognosis, carcinogenesis, and the onset of complications. In cirrhosis, fasting normal and postprandial hyperglycemia are often present, and evaluation by glucose tolerance test or continuous blood glucose measurement is also considered. Although no treatment strategy has been established, if renal function is maintained, metformin will be the first choice, but for renal dysfunction cases and metformin ineffective cases, insulin will be indicated. Although the efficacy and safety of incretin-related drugs and sodium-glucose cotransporter 2 inhibitors have not been established, they can be expected to be effective in cases with obesity. On the viewpoint of preventing sarcopenia and hepatocarcinogenesis, antidiabetic drugs should be selected. Exogenous insulin should be indicated for patients with Child C grade. This review discusses antidiabetic treatments for diabetes with liver cirrhosis.\",\"PeriodicalId\":170669,\"journal\":{\"name\":\"Interventions in Obesity & Diabetes\",\"volume\":\"38 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Interventions in Obesity & Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31031/IOD.2020.03.000566\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventions in Obesity & Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31031/IOD.2020.03.000566","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

糖尿病与约30%的肝硬化有关,并影响预后、癌变和并发症的发生。肝硬化常伴有空腹正常和餐后高血糖,也可考虑通过糖耐量试验或连续血糖测量进行评价。虽然目前还没有确定治疗策略,但在维持肾功能的情况下,二甲双胍将是首选,但对于肾功能不全和二甲双胍无效的病例,将会考虑胰岛素治疗。虽然肠促胰岛素相关药物和钠-葡萄糖共转运蛋白2抑制剂的有效性和安全性尚未确定,但可以预期它们对肥胖患者有效。从预防肌肉减少和肝癌发生的角度出发,选择降糖药物。外源性胰岛素应适用于儿童C级患者。本文就糖尿病合并肝硬化的降糖治疗进行综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Antidiabetic Treatments for Diabetes with Liver Cirrhosis
Diabetes is associated with about 30% of liver cirrhosis and affects prognosis, carcinogenesis, and the onset of complications. In cirrhosis, fasting normal and postprandial hyperglycemia are often present, and evaluation by glucose tolerance test or continuous blood glucose measurement is also considered. Although no treatment strategy has been established, if renal function is maintained, metformin will be the first choice, but for renal dysfunction cases and metformin ineffective cases, insulin will be indicated. Although the efficacy and safety of incretin-related drugs and sodium-glucose cotransporter 2 inhibitors have not been established, they can be expected to be effective in cases with obesity. On the viewpoint of preventing sarcopenia and hepatocarcinogenesis, antidiabetic drugs should be selected. Exogenous insulin should be indicated for patients with Child C grade. This review discusses antidiabetic treatments for diabetes with liver cirrhosis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Do We Really Need Carbohydrates? A Mini Review on Obesity and Diseases Nanotechnology in Diabetes Management Improved Beta-Cell Function and Altered Plasma Levels of GLP-1 During OMTT and Fasting Following Bariatric Surgery in Women with NGT Pyruvate May be a Novel Intervention of Diabetes Childhood Obesity: A Perspective on Compromises in Immunity, Cardiovascular Health, Metabolic Health of Children and Preventive Strategies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1